Long-term efficacy and safety of nilotinib therapy after imatinib failure in eosinophilic myeloproliferative neoplasm and ETV6-ABL rearrangement

Ann Hematol. 2015 Aug;94(8):1423-4. doi: 10.1007/s00277-015-2381-4. Epub 2015 Apr 23.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Benzamides / administration & dosage*
  • Benzamides / adverse effects
  • Humans
  • Imatinib Mesylate
  • Male
  • Myeloproliferative Disorders / diagnosis
  • Myeloproliferative Disorders / drug therapy*
  • Myeloproliferative Disorders / genetics*
  • Oncogene Proteins, Fusion / genetics*
  • Piperazines / administration & dosage*
  • Piperazines / adverse effects
  • Protein-Tyrosine Kinases / antagonists & inhibitors*
  • Protein-Tyrosine Kinases / genetics
  • Pyrimidines / administration & dosage*
  • Pyrimidines / adverse effects
  • Treatment Failure
  • Treatment Outcome

Substances

  • Benzamides
  • Oncogene Proteins, Fusion
  • Piperazines
  • Pyrimidines
  • TEL-ABL fusion protein, human
  • Imatinib Mesylate
  • Protein-Tyrosine Kinases
  • nilotinib